title: Addressing the spectrum of hypercholesterolemia.
abstract: The past decade has seen a major shift in management: Trials of HMG-CoA reductase inhibitors have suggested that cholesterol reduction offers greater protection against coronary artery disease than does antihypertensive therapy. Five patient vignettes provide guidelines for initiating therapy. The agents should be prescribed with restraint, often not until other measures have been exhausted.
authors.affiliation: University of Texas Southwestern Medical Center at Dallas, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Grundy
authors.forename: E L
authors.initials: EL
authors.lastname: Mazzaferri
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D018752:Diet, Fat-Restricted; D015444:Exercise; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000628:therapy*; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D019821:Simvastatin; D016540:Smoking Cessation
chemical_list: D000924:Anticholesteremic Agents; D008148:Lovastatin; D019821:Simvastatin